CIBC Private Wealth Group LLC increased its holdings in shares of Cooper Companies Inc (NYSE:COO) by 0.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,421 shares of the medical device company’s stock after buying an additional 368 shares during the period. CIBC Private Wealth Group LLC owned about 0.09% of Cooper Companies worth $10,796,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also made changes to their positions in the company. Essex Savings Bank purchased a new position in Cooper Companies in the 4th quarter valued at $25,000. Certified Advisory Corp purchased a new position in Cooper Companies in the 4th quarter valued at $25,000. Financial Gravity Companies Inc. purchased a new position in Cooper Companies in the 4th quarter valued at $46,000. Focused Wealth Management Inc purchased a new position in Cooper Companies in the 4th quarter valued at $127,000. Finally, CENTRAL TRUST Co lifted its holdings in Cooper Companies by 17.1% in the 4th quarter. CENTRAL TRUST Co now owns 513 shares of the medical device company’s stock valued at $131,000 after purchasing an additional 75 shares in the last quarter.
In related news, Director Allan E. Rubenstein purchased 348 shares of Cooper Companies stock in a transaction dated Monday, December 10th. The shares were acquired at an average price of $241.59 per share, for a total transaction of $84,073.32. Following the acquisition, the director now directly owns 4,524 shares in the company, valued at $1,092,953.16. The purchase was disclosed in a filing with the SEC, which is available through this link. 1.70% of the stock is owned by insiders.
NYSE COO opened at $278.00 on Thursday. Cooper Companies Inc has a 52 week low of $216.47 and a 52 week high of $288.51. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.16 and a current ratio of 2.03. The firm has a market cap of $13.62 billion, a PE ratio of 24.17, a P/E/G ratio of 2.17 and a beta of 0.88.
Cooper Companies (NYSE:COO) last posted its quarterly earnings results on Thursday, December 6th. The medical device company reported $2.87 EPS for the quarter, missing the consensus estimate of $2.96 by ($0.09). Cooper Companies had a return on equity of 17.70% and a net margin of 5.52%. The company had revenue of $651.50 million for the quarter, compared to analysts’ expectations of $645.25 million. During the same quarter in the prior year, the firm earned $2.65 EPS. The firm’s revenue was up 16.0% on a year-over-year basis. Sell-side analysts expect that Cooper Companies Inc will post 11.54 earnings per share for the current fiscal year.
The business also recently declared a semiannual dividend, which was paid on Friday, February 8th. Stockholders of record on Tuesday, January 22nd were issued a dividend of $0.03 per share. The ex-dividend date was Friday, January 18th. This represents a dividend yield of 0.02%. Cooper Companies’s dividend payout ratio is presently 0.52%.
A number of research analysts have weighed in on COO shares. KeyCorp restated a “buy” rating on shares of Cooper Companies in a report on Sunday, December 9th. Zacks Investment Research lowered Cooper Companies from a “hold” rating to a “sell” rating in a report on Tuesday, February 5th. Jefferies Financial Group raised their price objective on Cooper Companies to $305.00 and gave the company a “buy” rating in a report on Friday, December 7th. Goldman Sachs Group lowered Cooper Companies from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $233.00 to $221.00 in a report on Friday, January 4th. Finally, Wells Fargo & Co raised their price objective on Cooper Companies from $295.00 to $305.00 and gave the company an “outperform” rating in a report on Friday, December 7th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $289.44.
TRADEMARK VIOLATION NOTICE: This story was originally published by Equities Focus and is owned by of Equities Focus. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.equitiesfocus.com/2019/02/14/cooper-companies-inc-coo-stake-lifted-by-cibc-private-wealth-group-llc.html.
Cooper Companies Profile
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Featured Article: Compound Interest
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.